Stryker Corporation (SYK) Position Boosted by Koshinski Asset Management Inc.
Koshinski Asset Management Inc. boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 4.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,777 shares of the medical technology company’s stock after acquiring an additional 443 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Stryker were worth $1,514,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of SYK. Beach Investment Management LLC. purchased a new position in Stryker during the 2nd quarter valued at $1,924,000. First National Trust Co. boosted its holdings in Stryker by 6.2% during the 2nd quarter. First National Trust Co. now owns 9,625 shares of the medical technology company’s stock valued at $1,336,000 after acquiring an additional 561 shares during the period. Victory Capital Management Inc. boosted its holdings in Stryker by 12.8% during the 2nd quarter. Victory Capital Management Inc. now owns 19,892 shares of the medical technology company’s stock valued at $2,761,000 after acquiring an additional 2,253 shares during the period. Aviva PLC boosted its holdings in Stryker by 2.6% during the 2nd quarter. Aviva PLC now owns 209,048 shares of the medical technology company’s stock valued at $29,014,000 after acquiring an additional 5,330 shares during the period. Finally, Blue Chip Partners Inc. boosted its holdings in Stryker by 0.3% during the 2nd quarter. Blue Chip Partners Inc. now owns 1,781 shares of the medical technology company’s stock valued at $247,000 after acquiring an additional 6 shares during the period. Institutional investors own 74.88% of the company’s stock.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the transaction, the insider now directly owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 7.40% of the company’s stock.
Stryker Corporation (NYSE:SYK) opened at $160.27 on Thursday. The company has a market capitalization of $59,679.67, a price-to-earnings ratio of 25.27, a PEG ratio of 2.28 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. Stryker Corporation has a 1 year low of $119.17 and a 1 year high of $164.20.
Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.39 EPS. research analysts anticipate that Stryker Corporation will post 6.49 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 31st. Stockholders of record on Friday, December 29th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.17%. This is a positive change from Stryker’s previous quarterly dividend of $0.43. The ex-dividend date is Thursday, December 28th. Stryker’s payout ratio is presently 40.17%.
A number of equities analysts recently issued reports on SYK shares. SunTrust Banks restated a “buy” rating and set a $161.00 price objective on shares of Stryker in a report on Monday, October 2nd. Royal Bank of Canada reaffirmed a “buy” rating and set a $155.00 target price on shares of Stryker in a research report on Monday, October 2nd. Cowen set a $160.00 target price on Stryker and gave the company a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research lowered Stryker from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Finally, Robert W. Baird reaffirmed a “hold” rating and set a $161.00 target price on shares of Stryker in a research report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $156.60.
TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/stryker-corporation-syk-position-boosted-by-koshinski-asset-management-inc/1811911.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.